Rezera (formerly NodThera) filed for Nasdaq IPO as $RZRA, targeting Phase 3 for PAD in 2027 with NLRP3 inhibitor ruvonoflast. Novo Holdings and Blue Owl Capital each own 24%.
Roivant's brepocitinib (Lisraya) succeeded in two non-infectious uveitis trials, with plans to file for approval in H1 2027.
Deborah Waterhouse will take on the CEO post at CSL on Feb. 1 as the Australian pharma company attempts a turnaround after ...
FDA approves GSK and Ionis’ hepatitis B drug Hibsago early, but a boxed warning and weekly lab monitoring could slow uptake.
Endpoints News AI event featured Bayer, BMS, Takeda, Anthropic, and David Baker discussing AI slop, biosecurity risks, agents ...
Pfizer halts a Phase 2 ITP trial, Lycia targets a $227M IPO, Jemperli wins rectal cancer approval, plus news on AstraZeneca, ...
Rapport’s RAP-219, licensed from J&J, hits Phase 2 bipolar mania goal, with registrational trials planned for 2H 2027.
Median drug launch prices rose 24% from 2022-2025, net prices up 35%. Only 1 of 26 drugs met value benchmarks, causing $1B+ in excess spending.
A Massachusetts jury awards former Whitehead scientist David Sabatini $6M in his defamation suit against his accuser, who ...
ScionxBio signs first deal with Sanofi to screen mRNA candidates via its TERA platform. CEO Adi Gilboa-Geffen declined to ...
Epic launched a prescription marketplace with Amazon Pharmacy, Mark Cuban Cost Plus Drugs, Costco & Eli Lilly, letting ...
Astellas partners with AI Proteins, paying up to $400M, to develop miniprotein therapies using AI. CEO Chris Bahl targets ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results